

(19) World Intellectual Property  
Organization  
International Bureau



27 APR 2005



(43) International Publication Date  
13 May 2004 (13.05.2004)

PCT

(10) International Publication Number  
**WO 2004/039775 A2**

- (51) International Patent Classification<sup>7</sup>: **C07D** SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: **PCT/US2003/033964** (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (22) International Filing Date: 28 October 2003 (28.10.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/421,956 29 October 2002 (29.10.2002) US
- (71) Applicant (*for all designated States except US*): SMITHKLINE BEECHAM CORPORATION [US/US]; PO Box 7929, One Franklin Plaza, Philadelphia, PA 19101 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): BUSCH-PE-TERSEN, Jakob [DK/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). PALOVICH, Michael, R. [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). WIDDOWSON, Katherine, L. [CA/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US).
- (74) Agent: SIMON, Soma, G.; UW2220, 709 Swedeland Road, King of Prussia, PA 10406 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
- Declarations under Rule 4.17:**
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*
  - *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*
  - *of inventorship (Rule 4.17(iv)) for US only*
- Published:**
- *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: IL-8 RECEPTOR ANTAGONISTS

(57) Abstract: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

WO 2004/039775 A2

## **IL-8 RECEPTOR ANTAGONISTS**

### **FIELD OF THE INVENTION**

This invention relates to novel sulfonamide substituted diphenyl urea compounds,  
5 pharmaceutical compositions, processes for their preparation, and use thereof in treating  
IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2, and ENA-78 mediated diseases.

### **BACKGROUND OF THE INVENTION**

Many different names have been applied to Interleukin-8 (IL-8), such as  
10 neutrophil attractant/activation protein-1 (NAP-1), monocyte derived neutrophil  
chemotactic factor (MDNCF), neutrophil activating factor (NAF), and T-cell  
lymphocyte chemotactic factor. Interleukin-8 is a chemoattractant for neutrophils,  
basophils, and a subset of T-cells. It is produced by a majority of nucleated cells  
including macrophages, fibroblasts, endothelial and epithelial cells exposed to TNF,  
15 IL-1 $\alpha$ , IL-1 $\beta$  or LPS, and by neutrophils themselves when exposed to LPS or  
chemotactic factors such as FMLP. M. Baggiolini et al., *J. Clin. Invest.* 84, 1045  
(1989); J. Schroder et al, *J. Immunol.* 139, 3474 (1987) and *J. Immunol.* 144, 2223  
(1990) ; Strieter, et al., *Science* 243, 1467 (1989) and *J. Biol. Chem.* 264, 10621  
(1989); Cassatella et al., *J. Immunol.* 148, 3216 (1992).

20 GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$  and NAP-2 also belong to the chemokine family. Like  
IL-8 these chemokines have also been referred to by different names. For instance  
GRO $\alpha$ ,  $\beta$ ,  $\gamma$  have been referred to as MGSA $\alpha$ ,  $\beta$  and  $\gamma$  respectively (Melanoma Growth  
Stimulating Activity), see Richmond et al., *J. Cell Physiology* 129, 375 (1986) and  
Chang et al., *J. Immunol* 148, 451 (1992). All of the chemokines of the  $\alpha$ -family which  
25 possess the ELR motif directly preceding the CXC motif bind to the IL-8 B receptor  
(CXCR2).

IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2, and ENA-78 stimulate a number of  
functions in vitro. They have all been shown to have chemoattractant properties for  
neutrophils, while IL-8 and GRO $\alpha$  have demonstrated T-lymphocytes, and basophilic  
30 chemotactic activity. In addition IL-8 can induce histamine release from basophils  
from both normal and atopic individuals. GRO- $\alpha$  and IL-8 can in addition, induce

lysozomal enzyme release and respiratory burst from neutrophils. IL-8 has also been shown to increase the surface expression of Mac-1 (CD11b/CD18) on neutrophils without de novo protein synthesis. This may contribute to increased adhesion of the neutrophils to vascular endothelial cells. Many known diseases are characterized by massive neutrophil infiltration. As IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$  and NAP-2 promote the accumulation and activation of neutrophils, these chemokines have been implicated in a wide range of acute and chronic inflammatory disorders including psoriasis and rheumatoid arthritis, Baggiolini et al., FEBS Lett. 307, 97 (1992); Miller et al., Crit. Rev. Immunol. 12, 17 (1992); Oppenheim et al., Annu. Rev. Immunol. 9, 617 (1991); Seitz et al., J. Clin. Invest. 87, 463 (1991); Miller et al., Am. Rev. Respir. Dis. 146, 427 (1992); Donnelly et al., Lancet 341, 643 (1993). In addition the ELR chemokines (those containing the amino acids ELR motif just prior to the CXC motif) have also been implicated in angiostasis, Strieter et al., Science 258, 1798 (1992).

In vitro, IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$  and NAP-2 induce neutrophil shape change, chemotaxis, granule release, and respiratory burst, by binding to and activating receptors of the seven-transmembrane, G-protein-linked family, in particular by binding to IL-8 receptors, most notably the IL-8 $\beta$  receptor (CXCR2). Thomas et al., J. Biol. Chem. 266, 14839 (1991); and Holmes et al., Science 253, 1278 (1991). The development of non-peptide small molecule antagonists for members of this receptor family has precedent. For a review see R. Freidinger in: Progress in Drug Research, Vol. 40, pp. 33-98, Birkhauser Verlag, Basel 1993. Hence, the IL-8 receptor represents a promising target for the development of novel anti-inflammatory agents.

Two high affinity human IL-8 receptors (77% homology) have been characterized: IL-8R $\alpha$ , which binds only IL-8 with high affinity, and IL-8R $\beta$ , which has high affinity for IL-8 as well as for GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$  and NAP-2. See Holmes et al., supra; Murphy et al., Science 253, 1280 (1991); Lee et al., J. Biol. Chem. 267, 16283 (1992); LaRosa et al., J. Biol. Chem. 267, 25402 (1992); and Gayle et al., J. Biol. Chem. 268, 7283 (1993).

There remains a need for treatment, in this field, for compounds, which are capable of binding to the IL-8  $\alpha$  or  $\beta$  receptor. Therefore, conditions associated with an increase in IL-8 production (which is responsible for chemotaxis of neutrophil and T-

cells subsets into the inflammatory site) would benefit by compounds, which are inhibitors of IL-8 receptor binding.


### SUMMARY OF THE INVENTION

5 This invention provides for a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 a or b receptor and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In particular the chemokine is IL-8.

10 This invention also relates to a method of inhibiting the binding of IL-8 to its receptors in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).

The present invention also provides for the novel compounds of Formula (I), and pharmaceutical compositions comprising a compound of Formula (I), and a pharmaceutical carrier or diluent.

15 Compounds of Formula (I) useful in the present invention are represented by the structure:



20 wherein

$R_b$  is independently hydrogen,  $NR_6R_7$ , OH,  $OR_a$ ,  $C_{1-5}$ alkyl, aryl, aryl $C_{1-4}$ alkyl, aryl  $C_{2-4}$ alkenyl; cycloalkyl, cycloalkyl  $C_{1-5}$  alkyl, heteroaryl, heteroaryl $C_{1-4}$ alkyl, heteroaryl $C_{2-4}$  alkenyl, heterocyclic, heterocyclic  $C_{1-4}$ alkyl, or a heterocyclic  $C_{2-4}$ alkenyl moiety, all of which moieties may be optionally substituted one to three times independently by halogen; nitro; halosubstituted  $C_{1-4}$  alkyl;  $C_{1-4}$  alkyl; amino, 25 mono or di- $C_{1-4}$  alkyl substituted amine;  $OR_a$ ;  $C(O)R_a$ ;  $NR_aC(O)OR_a$ ;  $OC(O)NR_6R_7$ ; hydroxy;  $NR_9C(O)R_a$ ;  $S(O)_mR_a$ ;  $C(O)NR_6R_7$ ;  $C(O)OH$ ;  $C(O)OR_a$ ;  $S(O)_2NR_6R_7$ ;

NHS(O)<sub>2</sub>R<sub>a</sub>. Alternatively, the two R<sub>b</sub> substituents can join to form a 3-10 membered ring, optionally substituted and containing, in addition to carbon, independently, 1 to 3 NR<sub>a</sub>, O, S, SO, or SO<sub>2</sub> moieties which can be optionally unsaturated.

R<sub>a</sub> is an alkyl, aryl, arylC<sub>1-4</sub>alkyl, heteroaryl, heteroaryl C<sub>1-4</sub>alkyl, heterocyclic, COOR<sub>a</sub>,

5 or a heterocyclic C<sub>1-4</sub>alkyl moiety, all of which moieties may be optionally substituted;

m is an integer having a value of 1 to 3;

m' is 0, or an integer having a value of 1 or 2;

n is an integer having a value of 1 to 3;

q is 0, or an integer having a value of 1 to 10;

10 t is 0, or an integer having a value of 1 or 2;

s is an integer having a value of 1 to 3;

R<sub>1</sub> is independently selected from hydrogen; halogen; nitro; cyano; C<sub>1-10</sub> alkyl;

halosubstituted C<sub>1-10</sub> alkyl; C<sub>2-10</sub> alkenyl; C<sub>1-10</sub> alkoxy; halosubstituted C<sub>1-10</sub>alkoxy;

azide; S(O)<sub>t</sub>R<sub>4</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> S(O)<sub>t</sub>R<sub>4</sub>; hydroxy; hydroxy substituted C<sub>1-4</sub>alkyl; aryl; aryl

15 C<sub>1-4</sub> alkyl; aryl C<sub>2-10</sub> alkenyl; aryloxy; aryl C<sub>1-4</sub> alkyloxy; heteroaryl; heteroarylalkyl;

heteroaryl C<sub>2-10</sub> alkenyl; heteroaryl C<sub>1-4</sub> alkyloxy; heterocyclic, heterocyclic C<sub>1-4</sub>alkyl;

heterocyclicC<sub>1-4</sub>alkyloxy; heterocyclicC<sub>2-10</sub> alkenyl; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> NR<sub>4</sub>R<sub>5</sub>;

(CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>C(O)NR<sub>4</sub>R<sub>5</sub>; C<sub>2-10</sub> alkenyl C(O)NR<sub>4</sub>R<sub>5</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> C(O)NR<sub>4</sub>R<sub>10</sub>; S(O)<sub>3</sub>R<sub>8</sub>;

(CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> C(O)R<sub>11</sub>; C<sub>2-10</sub> alkenyl C(O)R<sub>11</sub>; C<sub>2-10</sub> alkenyl C(O)OR<sub>11</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>

20 C(O)OR<sub>11</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> OC(O)R<sub>11</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>NR<sub>4</sub>C(O)R<sub>11</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> C(NR<sub>4</sub>)NR<sub>4</sub>R<sub>5</sub>;

(CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> NR<sub>4</sub>C(NR<sub>5</sub>)R<sub>11</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> NHS(O)<sub>2</sub>R<sub>13</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> S(O)<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>; or two

R<sub>1</sub> moieties together may form O-(CH<sub>2</sub>)<sub>s</sub>O or a 5 to 6 membered saturated or unsaturated

ring, and wherein the alkyl, aryl, arylalkyl, heteroaryl, heterocyclic moieties may be optionally substituted;

25 R<sub>4</sub> and R<sub>5</sub> are independently hydrogen, optionally substituted C<sub>1-4</sub> alkyl, optionally

substituted aryl, optionally substituted aryl C<sub>1-4</sub>alkyl, optionally substituted heteroaryl,

optionally substituted heteroaryl C<sub>1-4</sub>alkyl, heterocyclic, heterocyclicC<sub>1-4</sub> alkyl, or R<sub>4</sub>

and R<sub>5</sub> together with the nitrogen to which they are attached form a 5 to 7 member ring

which may optionally comprise an additional heteroatom selected from O/N/S;

R<sub>6</sub> and R<sub>7</sub> are independently hydrogen, or a C<sub>1-4</sub> alkyl, heteroaryl, aryl, alkyl aryl, alkyl C<sub>1-4</sub> heteroalkyl or R<sub>6</sub> and R<sub>7</sub> together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom is selected from oxygen, nitrogen or sulfur, and which ring may be optionally substituted;

Y is hydrogen; halogen; nitro; cyano; halosubstituted C<sub>1-10</sub> alkyl; C<sub>1-10</sub> alkyl; C<sub>2-10</sub> alkenyl; C<sub>1-10</sub> alkoxy; halosubstituted C<sub>1-10</sub> alkoxy; azide; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>S(O)<sub>t</sub>R<sub>a</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>OR<sub>a</sub>; hydroxy; hydroxy substituted C<sub>1-4</sub>alkyl; aryl; aryl C<sub>1-4</sub> alkyl; aryloxy; arylC<sub>1-4</sub> alkyloxy; aryl C<sub>2-10</sub> alkenyl; heteroaryl; heteroarylalkyl; heteroaryl C<sub>1-4</sub> alkyloxy; heteroaryl C<sub>2-10</sub> alkenyl; heterocyclic; heterocyclic C<sub>1-4</sub>alkyl; heterocyclicC<sub>2-10</sub> alkenyl; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>NR<sub>4</sub>R<sub>5</sub>; C<sub>2-10</sub> alkenyl C(O)NR<sub>4</sub>R<sub>5</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>C(O)NR<sub>4</sub>R<sub>5</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> C(O)NR<sub>4</sub>R<sub>10</sub>; S(O)<sub>3</sub>R<sub>8</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>C(O)R<sub>11</sub>; C<sub>2-10</sub> alkenylC(O)R<sub>11</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>C(O)OR<sub>11</sub>; C<sub>2-10</sub>alkenylC(O)OR<sub>11</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>OC(O)R<sub>11</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>NR<sub>4</sub>C(O)R<sub>11</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> NHS(O)<sub>2</sub>R<sub>13</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> S(O)<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>C(NR<sub>4</sub>)NR<sub>4</sub>R<sub>5</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> NR<sub>4</sub>C(NR<sub>5</sub>)R<sub>11</sub>; or two Y moieties together may form O-(CH<sub>2</sub>)<sub>s</sub>-O or a 5 to 6 membered saturated or unsaturated ring; and wherein the alkyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic, heterocyclicalkyl groups may be optionally substituted;

R<sub>8</sub> is hydrogen or C<sub>1-4</sub> alkyl;

R<sub>9</sub> is hydrogen or a C<sub>1-4</sub> alkyl;

R<sub>10</sub> is C<sub>1-10</sub> alkyl C(O)<sub>2</sub>R<sub>8</sub>;

R<sub>11</sub> is hydrogen, optionally substituted C<sub>1-4</sub> alkyl, optionally substituted aryl, optionally substituted aryl C<sub>1-4</sub>alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC<sub>1-4</sub>alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC<sub>1-4</sub>alkyl;

R<sub>13</sub> is suitably C<sub>1-4</sub> alkyl, aryl, aryl C<sub>1-4</sub>alkyl, heteroaryl, heteroarylC<sub>1-4</sub>alkyl, heterocyclic, or heterocyclicC<sub>1-4</sub>alkyl;

or a pharmaceutically acceptable salt thereof.

**DETAILED DESCRIPTION OF THE INVENTION**

The compounds of Formula (I), may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of IL-8 or other chemokines which bind to the IL-8  $\alpha$  and  $\beta$  receptors. Chemokine mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted herein in the Methods of Treatment section.

Suitably,  $R_b$  is independently hydrogen,  $NR_6R_7$ , OH,  $OR_a$ ,  $C_{1-4}$ alkyl, aryl, aryl $C_{1-4}$ alkyl, aryl  $C_{2-4}$ alkenyl, heteroaryl, heteroaryl $C_{1-4}$ alkyl, heteroaryl $C_{2-4}$ alkenyl, heterocyclic, heterocyclic  $C_{1-4}$ alkyl, or a heterocyclic  $C_{2-4}$ alkenyl moiety, all of which moieties may be optionally substituted one to three times independently by halogen; nitro; halosubstituted  $C_{1-4}$  alkyl;  $C_{1-4}$  alkyl; amino, mono or di- $C_{1-4}$  alkyl substituted amine; cycloalkyl, cycloalkyl  $C_{1-5}$  alkyl,  $OR_a$ ;  $C(O)R_a$ ;  $NR_aC(O)OR_a$ ;  $OC(O)NR_6R_7$ ; aryloxy; aryl  $C_{1-4}$  oxy; hydroxy;  $C_{1-4}$  alkoxy;  $NR_9C(O)R_a$ ;  $S(O)_mR_a$ ;  $C(O)NR_6R_7$ ;  $C(O)OH$ ;  $C(O)OR_a$ ;  $S(O)_2NR_6R_7$ ;  $NHS(O)_2R_a$ ;

Alternatively, the two  $R_b$  substituents can join to form a 3-10 membered ring, optionally substituted and containing, in addition to carbon, independently, 1 to 3  $NR_9$ , O, S, SO, or  $SO_2$  moieties which can be optionally substituted.

Suitably,  $R_a$  is an alkyl, aryl, aryl $C_{1-4}$ alkyl, heteroaryl, heteroaryl  $C_{1-4}$ alkyl, heterocyclic, or a heterocyclic  $C_{1-4}$ alkyl moiety, all of which moieties may be optionally substituted.

Suitably  $R_1$  is independently selected from hydrogen; halogen; nitro; cyano; halosubstituted  $C_{1-10}$  alkyl, such as  $CF_3$ ;  $C_{1-10}$  alkyl, such as methyl, ethyl, isopropyl, or n-propyl;  $C_{2-10}$  alkenyl;  $C_{1-10}$  alkoxy, such as methoxy, or ethoxy; halosubstituted  $C_{1-10}$  alkoxy, such as trifluoromethoxy; azide;  $(CR_8R_9)_q S(O)_tR_4$ , wherein t is 0, 1 or 2; hydroxy; hydroxy  $C_{1-4}$ alkyl, such as methanol or ethanol; aryl, such as phenyl or naphthyl; aryl  $C_{1-4}$  alkyl, such as benzyl; aryloxy, such as phenoxy; aryl  $C_{1-4}$  alkyloxy, such as benzyloxy; heteroaryl; heteroarylalkyl; heteroaryl  $C_{1-4}$  alkyloxy; aryl  $C_{2-10}$  alkenyl; heteroaryl  $C_{2-10}$  alkenyl; heterocyclic  $C_{2-10}$  alkenyl;  $(CR_8R_9)_qNR_4R_5$ ;  $C_{2-10}$

alkenyl C(O)NR<sub>4</sub>R<sub>5</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>C(O)NR<sub>4</sub>R<sub>5</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>C(O)NR<sub>4</sub>R<sub>10</sub>; S(O)<sub>3</sub>H;  
 S(O)<sub>3</sub>R<sub>8</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>C(O)R<sub>11</sub>; C<sub>2-10</sub> alkenyl C(O)R<sub>11</sub>; C<sub>2-10</sub> alkenyl C(O)OR<sub>11</sub>;  
 (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> C(O)R<sub>11</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>C(O)OR<sub>11</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> OC(O)R<sub>11</sub>;  
 (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>NR<sub>4</sub>C(O)R<sub>11</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>C(NR<sub>4</sub>)NR<sub>4</sub>R<sub>5</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> NR<sub>4</sub>C(NR<sub>5</sub>)R<sub>11</sub>;  
 5 (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>NHS(O)<sub>2</sub>R<sub>13</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>S(O)<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>. All of the aryl, heteroaryl, and  
 heterocyclic containing moieties may be optionally substituted as defined herein below.

For use herein the term "the aryl, heteroaryl, and heterocyclic containing  
 moieties" refers to both the ring and the alkyl, or if included, the alkenyl rings, such as  
 aryl, arylalkyl, and aryl alkenyl rings. The term "moieties" and "rings" may be  
 10 interchangeably used throughout.

Suitably, R<sub>4</sub> and R<sub>5</sub> are independently hydrogen, optionally substituted C<sub>1-4</sub>  
 alkyl, optionally substituted aryl, optionally substituted aryl C<sub>1-4</sub>alkyl, optionally  
 substituted heteroaryl, optionally substituted heteroaryl C<sub>1-4</sub>alkyl, heterocyclic,  
 heterocyclicC<sub>1-4</sub> alkyl, or R<sub>4</sub> and R<sub>5</sub> together with the nitrogen to which they are  
 15 attached form a 5 to 7 member ring which may optionally comprise an additional  
 heteroatom selected from O/N/S.

Suitably, R<sub>8</sub> is independently hydrogen or C<sub>1-4</sub> alkyl.

Suitably, R<sub>9</sub> is hydrogen or a C<sub>1-4</sub> alkyl;

Suitably, q is 0 or an integer having a value of 1 to 10.

20 Suitably, R<sub>10</sub> is C<sub>1-10</sub> alkyl C(O)<sub>2</sub>R<sub>8</sub>, such as CH<sub>2</sub>C(O)<sub>2</sub>H or CH<sub>2</sub>C(O)<sub>2</sub>CH<sub>3</sub>.

Suitably, R<sub>11</sub> is hydrogen, C<sub>1-4</sub> alkyl, aryl, aryl C<sub>1-4</sub> alkyl, heteroaryl,  
 heteroaryl C<sub>1-4</sub>alkyl, heterocyclic, or heterocyclic C<sub>1-4</sub>alkyl.

Suitably, R<sub>12</sub> is hydrogen, C<sub>1-10</sub> alkyl, optionally substituted aryl or optionally  
 substituted arylalkyl.

25 Suitably, R<sub>13</sub> is C<sub>1-4</sub>alkyl, aryl, arylalkyl, heteroaryl, heteroarylC<sub>1-4</sub>alkyl,  
 heterocyclic, or heterocyclicC<sub>1-4</sub>alkyl, wherein all of the aryl, heteroaryl and  
 heterocyclic containing moieties may all be optionally substituted.

Suitably, Y is independently selected from hydrogen; halogen; nitro; cyano;  
 halosubstituted C<sub>1-10</sub> alkyl; C<sub>1-10</sub> alkyl; C<sub>2-10</sub> alkenyl; C<sub>1-10</sub> alkoxy; halosubstituted



C<sub>1-10</sub> alkoxy; azide; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> S(O)<sub>t</sub>R<sub>a</sub>; hydroxy; hydroxyC<sub>1-4</sub>alkyl; aryl; aryl C<sub>1-4</sub>alkyl; aryloxy; arylC<sub>1-4</sub> alkyloxy; heteroaryl; heteroarylalkyl; heteroaryl C<sub>1-4</sub> alkyloxy; heterocyclic, heterocyclic C<sub>1-4</sub>alkyl; aryl C<sub>2-10</sub> alkenyl; heteroaryl C<sub>2-10</sub> alkenyl; heterocyclic C<sub>2-10</sub> alkenyl; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> NR<sub>4</sub>R<sub>5</sub>; C<sub>2-10</sub> alkenyl C(O)NR<sub>4</sub>R<sub>5</sub>;  
 5 (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> C(O)NR<sub>4</sub>R<sub>5</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> C(O)NR<sub>4</sub>R<sub>10</sub>; S(O)<sub>3</sub>H; S(O)<sub>3</sub>R<sub>8</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> C(O)R<sub>11</sub>; C<sub>2-10</sub> alkenyl C(O)R<sub>11</sub>; C<sub>2-10</sub> alkenyl C(O)OR<sub>11</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> C(O)OR<sub>12</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> OC(O) R<sub>11</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub>C(NR<sub>4</sub>)NR<sub>4</sub>R<sub>5</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> NR<sub>4</sub>C(NR<sub>5</sub>)R<sub>11</sub>;  
 (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> NR<sub>4</sub>C(O)R<sub>11</sub>; (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> NHS(O)<sub>2</sub>R<sub>13</sub>; or (CR<sub>8</sub>R<sub>8</sub>)<sub>q</sub> S(O)<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>; or two  
 Y moieties together may form O-(CH<sub>2</sub>)<sub>s</sub>-O or a 5 to 6 membered saturated or  
 10 unsaturated ring. The aryl, heteroaryl and heterocyclic containing moieties noted above may all be optionally substituted as defined herein.

Suitably s is an integer having a value of 1 to 3.

When Y forms a dioxybridge, s is preferably 1. When Y forms an additional unsaturated ring, it is preferably 6 membered resulting in a naphthylene ring system.  
 15 These ring systems may be substituted 1 to 3 times by other Y moieties as defined above.

Suitably, R<sub>a</sub> is an alkyl, aryl C<sub>1-4</sub> alkyl, heteroaryl, heteroaryl-C<sub>1-4</sub>alkyl, heterocyclic, or a heterocyclicC<sub>1-4</sub> alkyl, wherein all of these moieties may all be optionally substituted.

20 Y is preferably a halogen, C<sub>1-4</sub> alkoxy, optionally substituted aryl, optionally substituted aryloxy or arylalkoxy, methylene dioxy, NR<sub>4</sub>R<sub>5</sub>, thio C<sub>1-4</sub>alkyl, thioaryl, halosubstituted alkoxy, optionally substituted C<sub>1-4</sub> alkyl, or hydroxy alkyl. Y is more preferably mono-substituted halogen, disubstituted halogen, mono-substituted alkoxy, disubstituted alkoxy, methylenedioxy, aryl, or alkyl, more preferably these groups are  
 25 mono or di-substituted in the 2'- position or 2', 3'-position.

While Y may be substituted in any of the ring positions, n is preferably one. While both R<sub>1</sub> and Y can both be hydrogen, it is preferred that at least one of the rings is substituted, preferably both rings are substituted.

As used herein, "optionally substituted" unless specifically defined shall mean  
 30 such groups as halogen, such as fluorine, chlorine, bromine or iodine; hydroxy;

hydroxy substituted C<sub>1-10</sub>alkyl; C<sub>1-10</sub> alkoxy, such as methoxy or ethoxy; S(O)<sub>m'</sub> C<sub>1-10</sub> alkyl, wherein m' is 0, 1 or 2, such as methyl thio, methyl sulfinyl or methyl sulfonyl; amino, mono & di-substituted amino, such as in the NR<sub>4</sub>R<sub>5</sub> group; NHC(O)R<sub>4</sub>; C(O)NR<sub>4</sub>R<sub>5</sub>; C(O)OH; S(O)<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>; NHS(O)<sub>2</sub>R<sub>20</sub>, C<sub>1-10</sub> alkyl, such as methyl, ethyl, propyl, isopropyl, or t-butyl; halosubstituted C<sub>1-10</sub> alkyl, such as CF<sub>3</sub>; an optionally substituted aryl, such as phenyl, or an optionally substituted arylalkyl, such as benzyl or phenethyl, optionally substituted heterocyclic, optionally substituted heterocyclicalkyl, optionally substituted heteroaryl, optionally substituted heteroaryl alkyl, wherein these aryl, heteroaryl, or heterocyclic moieties may be substituted one to two times by halogen; hydroxy; hydroxy substituted alkyl; C<sub>1-10</sub> alkoxy; S(O)<sub>m</sub> C<sub>1-10</sub> alkyl; amino, mono & di-substituted alkyl amino, such as in the NR<sub>4</sub>R<sub>5</sub> group; C<sub>1-10</sub> alkyl, or halosubstituted C<sub>1-10</sub> alkyl, such as CF<sub>3</sub>.

R<sub>20</sub> is suitably C<sub>1-4</sub> alkyl, aryl, aryl C<sub>1-4</sub>alkyl, heteroaryl, heteroarylC<sub>1-4</sub>alkyl, heterocyclic, or heterocyclicC<sub>1-4</sub>alkyl.

Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid. In addition, pharmaceutically acceptable salts of compounds of Formula (I) may also be formed with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations.

The following terms, as used herein, refer to:

- "halo" - all halogens, that is chloro, fluoro, bromo and iodo.
- "C<sub>1-10</sub>alkyl" or "alkyl" - both straight and branched chain moieties of 1 to 10 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl, *tert*-butyl, *n*-pentyl and the like.

• "cycloalkyl" is used herein to mean cyclic moiety, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like.

• "alkenyl" is used herein at all occurrences to mean straight or branched chain moiety of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl and the like.

• "aryl" - phenyl and naphthyl;

• "heteroaryl" (on its own or in any combination, such as "heteroaryloxy", or "heteroaryl alkyl") - a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene, quinoline, isoquinoline, quinazolinyl, pyridine, pyrimidine, oxazole, tetrazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole.

• "heterocyclic" (on its own or in any combination, such as "heterocyclicalkyl") - a saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, tetrahydropyran, thiomorpholine, or imidazolidine. Furthermore, sulfur may be optionally oxidized to the sulfone or the sulfoxide.

• "arylalkyl" or "heteroarylalkyl" or "heterocyclicalkyl" is used herein to mean C<sub>1-10</sub> alkyl, as defined above, attached to an aryl, heteroaryl or heterocyclic moiety, as also defined herein, unless otherwise indicated.

• "sulfinyl" - the oxide S (O) of the corresponding sulfide, the term "thio" refers to the sulfide, and the term "sulfonyl" refers to the fully oxidized S(O)<sub>2</sub> moiety.

• "wherein two R<sub>1</sub> moieties (or two Y moieties) may together form a 5 or 6 membered saturated or unsaturated ring" is used herein to mean the formation of an aromatic ring system, such as naphthalene, or is a phenyl moiety having attached a 6 membered partially saturated or unsaturated ring such as a C<sub>6</sub> cycloalkenyl, i.e. hexene, or a C<sub>5</sub> cycloalkenyl moiety, such as cyclopentene.

Illustrative compounds of Formula (I) include:

N-[4-chloro-2-hydroxy-3-(4-methyl-piperazine -1-sulfonyl)-phenyl]-N'-(2-chloro-3-fluorophenyl) urea;


N-[4-chloro-2-hydroxy-3-(4-(2-hydroxyethyl)-piperazine-1-sulfonyl)phenyl]-N'-(2-chloro-3-fluorophenyl) urea;

- 5 N-[4-chloro-2-hydroxy-3-(1-piperazinylsulfonyl)phenyl]-N'-(2-chloro-3-fluorophenyl) urea or a pharmaceutically acceptable salt thereof.

The above mentioned compounds have improved developability characteristics relative to their most closely related counterparts which have been claimed previously. In  
10 addition, the potency towards the therapeutic target has been maintained or improved.

### **METHODS OF PREPARATION**

The compounds of Formulas (I) may be obtained by applying synthetic procedures, some of which are illustrated in the Scheme 1 below. The synthesis  
15 provided for in these Schemes is applicable for the producing compounds of Formulas (I) having a variety of different R, R' and Aryl (optionally substituted) groups which are reacted, employing optional substituents which are suitably protected, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed. Once the urea nucleus  
20 has been established, further compounds of these formulas may be prepared by applying standard techniques for functional group interconversion, well known in the art.

Scheme 1Example 11a) 2-chloro-3-fluorobenzoic acid

- 5 A solution of 3-fluorobenzoic acid (4.02 g, 28.71 mmol) in 20 mL of THF was added dropwise to a suspension of TMEDA (10.00mL, 66.3mmol) and 1.3M sec-BuLi (48mL, 62.4mmol) in 50 mL of THF at  $-90^\circ\text{C}$ . The mixture was stirred at  $-90^\circ\text{C}$  for 35min. The mixture was warmed to  $-78^\circ\text{C}$  when a solution of hexachloroethane (27.0g, 113.9mmol) in 50 mL of THF was added. After 20 h, the reaction was
- 10 quenched with water and diluted with diethyl ether. The bilayer was adjusted to pH  $\sim 1-2$  with conc. HCl. The organic layer was washed with water, brine, dried and concentrated to give 30.4g crude as a tan solid, which was washed with hexane to give 3.728g (74%) of the desired product **1a** (light tan solid). MS (m/z) 175.2 (M+H).

15 1b) 3-chloro-2-fluoro-benzoyl azide

A suspension of 2-chloro-3-fluorobenzoic acid (example 1a) (2.704g, 15.54mmol) in 25 mL of oxalyl chloride was heated to reflux for 2 h. The solution was cooled and

concentrated to give the crude acid chloride 3.13g as a brown liquid which was directly used in the next step.

A solution of NaN<sub>3</sub> (2.79g, 43mmol) in 10 mL of water was added dropwise to a solution of the crude acid chloride (3.13g) in 20mL acetone at 0°C. After 15 min, the solution was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with water and brine. The organic layer was dried and concentrated to give a brown liquid which was filtered through silica gel using ethyl acetate/hexane (5/95, v/v) to yield 2.97g (96%) of **1b** (colorless liquid).

The compound was used without further purification.

10 1c) 2-(2-tert-Butyl-6-chloro-benzooxazole-7-sulfonyl)-piperazine-1-carboxylic acid tert-butyl ester

The solution of 2-tert-butyl-6-chloro-benzooxazole-7-sulfonyl chloride (10.75 g, 34.9 mmol) in 100 mL of THF was cooled to 0 °C, Et<sub>3</sub>N (3.47 mL, 24.9mmol) and then Boc-piperazine (5.0g, 26.8mmol) were added. The resulting mixture was stirred for 20 h, warming to room temperature. The mixture was poured into water, extracted with EtOAc and washed with another portion of water; organic layers were dried and concentrated. Purification by column chromatography on silica gel, eluting with ethyl acetate/hexane (30/70, v/v), yielded 11.12 g (91%) desired product **1c**. LC-MS (m/z) 458.2 (M+H).

20

1d) 4-(3-Amino-6-chloro-2-hydroxy-benzenesulfonyl)-piperazine-1-carboxylic acid tert-butyl ester.

The solution of starting material **1c**(11.12g) in dioxane (20mL) was treated with water (11mL) and conc. H<sub>2</sub>SO<sub>4</sub> (11mL). The mixture was heated to reflux for 12 h. The reaction mixture was concentrated and then basified the residue to pH ~14 with 50% aq NaOH. (Boc)<sub>2</sub>O (5.6 g, 1.05eq) and 100 mL of AcOEt were added, the resulting mixture was stirred at room temperature for 16 h. The mixture was separated, the water layer was extracted with EtOAc, organic layers were combined, dried and concentrated. Purification by column chromatography on silica gel, eluting with ethyl acetate/hexane

(30/70, v/v), yielded 8.18 g (85 %) desired product **1d**. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 6.85 (m, 2H), 3.48 (t, 4H), 3.25 (t, 4H), 1.47 (s, 9H).

1e) 4-(6-chloro-3-[3-(2-chloro-3-fluorophenyl)-ureido]-2-hydroxy-benzenesulfonyl)-piperazine-1-carboxylic acid *tert*-butyl ester

A solution of **1d** (3.8g, 9.7 mmol) and 3-chloro-2-fluorobenzoyl azide (**1b**) (2.9g, 14.5 mmol) in 5mL of N,N-dimethylformamide was stirred at room temperature for 18 h. The mixture was diluted with ethyl acetate and washed with water to give the crude material. Purification by column chromatography on silica gel, eluting with ethyl acetate/hexane (20/80, v/v), gave 3.6g (66 %) of **1e**. LC-MS (m/z) 562.8 (M+H).

1f) 1-(2-Chloro-3-fluorophenyl)-3-[4-chloro-2-hydroxy-3-(piperazine-1-sulfonyl)-phenyl]-urea hydrochloride

A solution of 3.6g Boc-product in 20 mL of 4N HCl in dioxane was stirred at room temperature for 2 h and the solvent was evaporated. The residue was recrystallized from methanol and ethyl acetate to give the title product 2.9g, (60%). LC-MS (m/z) 463.0 (M+H).

Example 2

2a) *tert*-Butyl-6-chloro-7-(4-(2-methoxyethyl)-piperazine-1-sulfonyl)-benzooxazole

Followed the general procedure described in Example 1c, 2-*tert*-butyl-6-chloro-benzooxazole-7-sulfonyl chloride coupled with 2-methoxy-ethyl-piperazine to give the desired product **2a**, 1.11g (82%). LC-MS (m/z) 416.2 (M+H).

2b) 6-Amino-3-chloro-2-[4-(2-methoxyethyl)-piperazine-1-sulfonyl]-phenol

Followed the general procedure described in Example 1d, *tert*-butyl-6-chloro-7-(4-(2-methoxy-ethyl)-piperazine-1-sulfonyl)-benzooxazole was hydrolized to give crude **2b** which was used in the next step without further purification.

2c) 1-(2-Chloro-3-fluoro-phenyl)-3-[4-chloro-2-hydroxy-3-[4-(2-methoxyethyl)-piperazine-1-sulfonyl]-phenyl]-urea

Followed the general procedure described in Example 1e, 6-amino-3-chloro-2-[4-(2-methoxyl-ethyl)-piperazine-1-sulfonyl]-phenol and 3-chloro-2-fluorobenzoyl azide were coupled to give 168 mg (20 % from 2a) of the product 2c (isolated as the trifluoroacetic acid salt following RP-HPLC purification). LC-MS (m/z) 521.2 (M+H).

5

2d) 1-(2-Chloro-3-fluorophenyl)-3-[4-chloro-2-hydroxy-3-[4-(2-hydroxyethyl)-piperazine-1-sulfonyl]-phenyl]-urea

Under Ar, to the suspension of 2c trifluoroacetic acid salt (100mg, 0.16mmol) in 3mL of dichloromethane was added boron tribromide (0.63mL, 0.63mmol). The mixture was stirred at room temperature overnight. After quenching with methanol, solid produced. The mixture was filtered, solid was collected. Purification upon Gilson HPLC, eluting with acetonitrile/water/0.1% TFA (10/90, v/v to 90/10, v/v, over 10min) yielding 66mg (76%) of the title compound 2d. LC-MS (m/z) 507.2 (M+H).

15 3a) 2-tert-Butyl-6-chloro-7-(4-methylpiperazine-1-sulfonyl)-benzooxazole

Followed the general procedure described in Example 1c, 2-tert-butyl-6-chloro-benzooxazole-7-sulfonyl chloride coupled with methyl-piperazine to give the desired product 3a, 600mg (53%). LC-MS (m/z) 372.0 (M+H).

20 3b) 6-Amino-3-chloro-2-(4-methylpiperazine-1-sulfonyl)-phenol

Followed the general procedure described in Example 1d, 2-tert-Butyl-6-chloro-7-(4-methyl-piperazine-1-sulfonyl)-benzooxazole was hydrolyzed to give 3b, 441mg (89%). LC-MS (m/z) 306.2 (M+H).

25 3c) 1-(2-Chloro-3-fluorophenyl)-3-[4-chloro-2-hydroxy-3-(4-methylpiperazine-1-sulfonyl)-phenyl]-urea

Followed the general procedure described in Example 1e, 6-amino-3-chloro-2-(4-methyl-piperazine-1-sulfonyl)-phenol and 3-chloro-2-fluoro-benzoyl azide (1b) were coupled to give 203mg (30%) of the title product 3c. LC-MS (m/z) 477.0 (M+H).

30



### METHOD OF TREATMENT

The compounds of Formula (I), or a pharmaceutically acceptable salt thereof can be used in the manufacture of a medicine for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated IL-8 cytokine production by such mammal's cell, such as but not limited to monocytes and/or macrophages, or other chemokines which bind to the IL-8  $\alpha$  or  $\beta$  receptor, also referred to as the type I or type II receptor.

Accordingly, the present invention provides a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8  $\alpha$  or  $\beta$  receptor and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In particular, the chemokines are IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2 or ENA-78.

The compounds of Formula (I) are administered in an amount sufficient to inhibit cytokine function, in particular IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2 or ENA-78, such that they are biologically regulated down to normal levels of physiological function, or in some case to subnormal levels, so as to ameliorate the disease state. Abnormal levels of IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2 or ENA-78 for instance in the context of the present invention, constitute: (i) levels of free IL-8 greater than or equal to 1 picogram per mL; (ii) any cell associated IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2 or ENA-78 above normal physiological levels; or (iii) the presence of IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2 or ENA-78 above basal levels in cells or tissues in which IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2 or ENA-78 respectively, is produced.

The compounds of Formula (I), in generally have been shown to have a longer  $t_{1/2}$  and improved oral bioavailability over the compounds disclosed in WO 96/25157 and WO 97/29743 whose disclosures are incorporated herein by reference.

There are many disease states in which excessive or unregulated IL-8 production is implicated in exacerbating and/or causing the disease. Chemokine mediated diseases include psoriasis, atopic dermatitis, arthritis (either osteo- or rheumatoid), asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cardiac and

renal reperfusion injury, glomerulonephritis, thrombosis, graft vs. host reaction, alzheimers disease, allograft rejections, malaria, restinosis, angiogenesis, atherosclerosis, osteoporosis, gingivitis, viral diseases such as rhinovirus or undesired hematopoietic stem cell release.

5           These diseases are primarily characterized by massive neutrophil infiltration, T-cell infiltration, or neovascular growth, and are associated with increased IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2 or ENA-78 production which is responsible for the chemotaxis of neutrophils into the inflammatory site or the directional growth of endothelial cells. In contrast to other inflammatory cytokines (IL-1, TNF, and IL-6), IL-8, GRO $\alpha$ ,  
10   GRO $\beta$ , GRO $\gamma$ , NAP-2 or ENA-78 have the unique property of promoting neutrophil chemotaxis, enzyme release including but not limited to elastase release as well as superoxide production and activation. The  $\alpha$ -chemokines but particularly, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2 or ENA-78, working through the IL-8 type I or II receptor can promote the neovascularization of tumors by promoting the directional growth of  
15   endothelial cells. Therefore, the inhibition of IL-8 induced chemotaxis or activation would lead to a direct reduction in the neutrophil infiltration.

Recent evidence also implicates the role of chemokines in the treatment of HIV infections, Littleman *et al.*, Nature 381, pp. 661 (1996) and Koup *et al.*, Nature 381, pp. 667 (1996).

20           Present evidence also indicates the use of IL-8 inhibitors in the treatment of atherosclerosis. The first reference, Boisvert et al., J. Clin. Invest., 1998, 101:353-363 shows, through bone marrow transplantation, that the absence of IL-8 receptors on stem cells (and, therefore, on monocytes/macrophages) leads to a reduction in the development of atherosclerotic plaques in LDL receptor deficient mice. Additional  
25   supporting references are: Apostolopoulos, et al., Arterioscler. Thromb. Vasc. Biol. 1996, 16:1007-1012; Liu, et al., Arterioscler. Thromb. Vasc. Biol. 1997, 17:317-323; Rus, et al., Atherosclerosis 1996, 127:263-271.; Wang et al., J. Biol. Chem. 1996, 271:8837-8842; Yue, et al., Eur. J. Pharmacol. 1993, 240:81-84; Koch, et al., Am. J. Pathol., 1993, 142:1423-1431.; Lee, et al., Immunol. Lett., 1996, 53, 109-113.; and  
30   Terkeltaub et al., Arterioscler. Thromb., 1994, 14:47-53.

The present invention also provides for a means of treating, in an acute setting, as well as preventing, in those individuals deemed susceptible to, CNS injuries by the chemokine receptor antagonist compounds of Formula (I).

CNS injuries as defined herein include both open or penetrating head trauma, such as by surgery, or a closed head trauma injury, such as by an injury to the head region. Also included within this definition is ischemic stroke, particularly to the brain area.

Ischemic stroke may be defined as a focal neurologic disorder that results from insufficient blood supply to a particular brain area, usually as a consequence of an embolus, thrombi, or local atheromatous closure of the blood vessel. The role of inflammatory cytokines in this area has been emerging and the present invention provides a mean for the potential treatment of these injuries. Relatively little treatment, for an acute injury such as these has been available.

TNF- $\alpha$  is a cytokine with proinflammatory actions, including endothelial leukocyte adhesion molecule expression. Leukocytes infiltrate into ischemic brain lesions and hence compounds which inhibit or decrease levels of TNF would be useful for treatment of ischemic brain injury. See Liu *et al.*, Stroke, Vol. 25., No. 7, pp. 1481-88 (1994) whose disclosure is incorporated herein by reference.

Models of closed head injuries and treatment with mixed 5-LO/CO agents is discussed in Shohami *et al.*, J. of Vasc & Clinical Physiology and Pharmacology, Vol. 3, No. 2, pp. 99-107 (1992) whose disclosure is incorporated herein by reference. Treatment which reduced edema formation was found to improve functional outcome in those animals treated.

The compounds of Formula (I) are administered in an amount sufficient to inhibit IL-8, binding to the IL-8 alpha or beta receptors, from binding to these receptors, such as evidenced by a reduction in neutrophil chemotaxis and activation. The discovery that the compounds of Formula (I) are inhibitors of IL-8 binding is based upon the effects of the compounds of Formulas (I) in the *in vitro* receptor binding assays which are described herein. The compounds of Formula (I) have been shown to be inhibitors of type II IL-8 receptors.

As used herein, the term "IL-8 mediated disease or disease state" refers to any and all disease states in which IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2 or ENA-78 plays a role, either by production of IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2 or ENA-78 themselves, or by IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , NAP-2 or ENA-78 causing another  
5 monokine to be released, such as but not limited to IL-1, IL-6 or TNF. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to IL-8, would therefore be considered a disease state mediated by IL-8.

As used herein, the term "chemokine mediated disease or disease state" refers to  
10 any and all disease states in which a chemokine which binds to an IL-8  $\alpha$  or  $\beta$  receptor plays a role, such as but not limited to IL-8, GRO- $\alpha$ , GRO- $\beta$ , GRO $\gamma$ , NAP-2 or ENA-78. This would include a disease state in which, IL-8 plays a role, either by production of IL-8 itself, or by IL-8 causing another monokine to be released, such as but not limited to IL-1, IL-6 or TNF. A disease state in which, for instance, IL-1 is a major  
15 component, and whose production or action, is exacerbated or secreted in response to IL-8, would therefore be considered a disease stated mediated by IL-8.

As used herein, the term "cytokine" refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response. A cytokine includes, but  
20 is not limited to, monokines and lymphokines, regardless of which cells produce them. For instance, a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte. Many other cells however also produce monokines, such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epidermal keratinocytes  
25 and B-lymphocytes. Lymphokines are generally referred to as being produced by lymphocyte cells. Examples of cytokines include, but are not limited to, Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor-alpha (TNF- $\alpha$ ) and Tumor Necrosis Factor beta (TNF- $\beta$ ).

As used herein, the term "chemokine" refers to any secreted polypeptide that affects  
30 the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response, similar to the term "cytokine" above. A

chemokine is primarily secreted through cell transmembranes and causes chemotaxis and activation of specific white blood cells and leukocytes, neutrophils, monocytes, macrophages, T-cells, B-cells, endothelial cells and smooth muscle cells. Examples of chemokines include, but are not limited to IL-8, GRO- $\alpha$ , GRO- $\beta$ , GRO- $\gamma$ , NAP-2, ENA-78, IP-10, MIP-1 $\alpha$ , MIP- $\beta$ , PF4, and MCP 1, 2, and 3.

In order to use a compound of Formula (I) or a pharmaceutically acceptable salt thereof in therapy, it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. This invention, therefore, also relates to a pharmaceutical composition comprising an effective, non-toxic amount of a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent.

Compounds of Formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions incorporating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation. The compounds of Formula (I) may be administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical carriers according to conventional procedures. The compounds of Formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.

A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25mg to about 1g. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.

Compounds of Formula (I) may be administered topically, that is by non-systemic administration. This includes the application of a compound of Formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the Formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1% to 1% w/w of the Formulation.

Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.

Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin

such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a

- 5 polyoxyethylene derivative thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as siliceous silicas, and other ingredients such as lanolin, may also be included.

Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a  
10 suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100°C for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the  
15 container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.

20 Compounds of formula (I) may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques. Compounds of Formula  
25 (I) may also be administered by inhalation, that is by intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.

For all methods of use disclosed herein for the compounds of Formula (I) the daily oral dosage regimen will preferably be from about 0.01 to about 80 mg/kg of total  
30 body weight. The daily parenteral dosage regimen about 0.001 to about 80 mg/kg of total body weight. The daily topical dosage regimen will preferably be from 0.1 mg to

150 mg, administered one to four, preferably two or three times daily. The daily inhalation dosage regimen will preferably be from about 0.01 mg/kg to about 1 mg/kg per day. It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.

The invention will now be described by reference to the following biological examples, which are merely illustrative and are not to be construed as a limitation of the scope of the present invention.

### **BIOLOGICAL EXAMPLES**

The IL-8, and GRO- $\alpha$  chemokine inhibitory effects of compounds of the present invention are determined by the following *in vitro* assay:

#### **Receptor Binding Assays:**

[<sup>125</sup>I] IL-8 (human recombinant) is obtained from Amersham Corp., Arlington Heights, IL, with specific activity 2000 Ci/mmol. GRO- $\alpha$  is obtained from NEN- New England Nuclear. All other chemicals are of analytical grade. High levels of recombinant human IL-8 type  $\alpha$  and  $\beta$  receptors were individually expressed in Chinese hamster ovary cells as described previously (Holmes, *et al.*, Science, **1991**, 253, 1278). The Chinese hamster ovary membranes were homogenized according to a previously described protocol (Haour, *et al.*, J. Biol. Chem., 249 pp 2195-2205 (1974)). Except that the homogenization buffer is changed to 10mM Tris-HCL, 1mM MgSO<sub>4</sub>, 0.5mM EDTA (ethylene-diaminetetra-acetic acid), 1mM PMSF ( $\alpha$ -toluenesulphonyl fluoride), 0.5 mg/L Leupeptin, pH 7.5. Membrane protein concentration is determined using Pierce Co. micro-assay kit using bovine serum albumin as a standard. All assays are performed in a 96-well micro plate format. Each reaction mixture contains <sup>125</sup>I IL-8



(0.25 nM) or  $^{125}\text{I}$  GRO- $\alpha$  and 0.5  $\mu\text{g/mL}$  of IL-8R $\alpha$  or 1.0  $\mu\text{g/mL}$  of IL-8R $\beta$  membranes in 20 mM Bis-Trispropane and 0.4 mM Tris HCl buffers, pH 8.0, containing 1.2 mM  $\text{MgSO}_4$ , 0.1 mM EDTA, 25 mM Na and 0.03% CHAPS. In addition, drug or compound of interest is added which has been pre-dissolved in DMSO so as to reach a final concentration of between 0.01nM and 100  $\mu\text{M}$ . The assay is initiated by addition of  $^{125}\text{I}$ -IL-8. After 1 hour at room temperature the plate is harvested using a Tomtec 96-well harvester onto a glass fiber filtermat blocked with 1% polyethylenimine/ 0.5% BSA and washed 3 times with 25 mM NaCl, 10 mM TrisHCl, 1 mM  $\text{MgSO}_4$ , 0.5 mM EDTA, 0.03 % CHAPS, pH 7.4. The filter is then dried and counted on the Betaplate liquid scintillation counter. The recombinant IL-8 R $\alpha$ , or Type I, receptor is also referred to herein as the non-permissive receptor and the recombinant IL-8 R $\beta$ , or Type II, receptor is referred to as the permissive receptor.

Representative compounds of Formula (I), Examples 1 to 106 have exhibited positive inhibitory activity in this assay at  $\text{IC}_{50}$  levels < 30  $\mu\text{M}$ .

#### 15 Chemotaxis Assay:

The *in vitro* inhibitory properties of these compounds are determined in the neutrophil chemotaxis assay as described in Current Protocols in Immunology, vol. I, Suppl 1, Unit 6.12.3., whose disclosure is incorporated herein by reference in its entirety. Neutrophils were isolated from human blood as described in Current Protocols in Immunology Vol. I, Suppl 1 Unit 7.23.1, whose disclosure is incorporated herein by reference in its entirety. The chemoattractants IL-8, GRO- $\alpha$ , GRO- $\beta$ , GRO- $\gamma$  and NAP-2 are placed in the bottom chamber of a 48 multiwell chamber (Neuro Probe, Cabin John, MD) at a concentration between 0.1 and 100 nM. The two chambers are separated by a 5  $\mu\text{M}$  polycarbonate filter. When compounds of this invention are tested, they are mixed with the cells (0.001 - 1000 nM) just prior to the addition of the cells to the upper chamber. Incubation is allowed to proceed for between about 45 and 90 min at about 37°C in a humidified incubator with 5%  $\text{CO}_2$ . At the end of the incubation period, the polycarbonate membrane is removed and the top side washed, the membrane then stained using the Diff Quick staining protocol (Baxter Products, McGaw Park, IL, USA). Cells which have chemotaxed to the chemokine are visually

counted using a microscope. Generally, four fields are counted for each sample, these numbers are averaged to give the average number of cells which had migrated. Each sample is tested in triplicate and each compound repeated at least four times. To certain cells (positive control cells) no compound is added, these cells represent the maximum chemotactic response of the cells. In the case where a negative control (unstimulated) is desired, no chemokine is added to the bottom chamber. The difference between the positive control and the negative control represents the chemotactic activity of the cells.

#### **Elastase Release Assay:**

The compounds of this invention are tested for their ability to prevent Elastase release from human neutrophils. Neutrophils are isolated from human blood as described in Current Protocols in Immunology Vol. I, Suppl 1 Unit 7.23.1. PMNs  $0.88 \times 10^6$  cells suspended in Ringer's Solution (NaCl 118, KCl 4.56,  $\text{NaHCO}_3$  25,  $\text{KH}_2\text{PO}_4$  1.03, Glucose 11.1, HEPES 5 mM, pH 7.4) are placed in each well of a 96 well plate in a volume of 50 ul. To this plate is added the test compound (0.001 - 1000 nM) in a volume of 50 ul, Cytochalasin B in a volume of 50 ul (20ug/ml) and Ringers buffer in a volume of 50 ul. These cells are allowed to warm (37 °C, 5% CO<sub>2</sub>, 95% RH) for 5 min before IL-8, GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$  or NAP-2 at a final concentration of 0.01 - 1000 nM was added. The reaction is allowed to proceed for 45 min before the 96 well plate is centrifuged (800 xg 5 min.) and 100 ul of the supernatant removed. This supernatant is added to a second 96 well plate followed by an artificial elastase substrate (MeOSuc-Ala-Ala-Pro-Val-AMC, Nova Biochem, La Jolla, CA) to a final concentration of 6 ug/ml dissolved in phosphate buffered saline. Immediately, the plate is placed in a fluorescent 96 well plate reader (Cytofluor 2350, Millipore, Bedford, MA) and data collected at 3 min intervals according to the method of Nakajima et al J. Biol. Chem. 254 4027 (1979). The amount of Elastase released from the PMNs is calculated by measuring the rate of MeOSuc-Ala-Ala-Pro-Val-AMC degradation.

#### **TNF- $\alpha$ in Traumatic Brain Injury Assay**

The present assay provides for examination of the expression of tumor necrosis factor mRNA in specific brain regions which follow experimentally induced lateral fluid-percussion traumatic brain injury (TBI) in rats. Adult Sprague-Dawley rats (n=42) were anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and subjected to lateral fluid-percussion brain

injury of moderate severity (2.4 atm.) centered over the left temporoparietal cortex (n=18), or "sham" treatment (anesthesia and surgery without injury, n=18). Animals are sacrificed by decapitation at 1, 6 and 24 hr. post injury, brains removed, and tissue samples of left (injured) parietal cortex (LC), corresponding area in the contralateral right cortex (RC), cortex adjacent to injured parietal cortex (LA), corresponding adjacent area in the right cortex (RA), left hippocampus (LH) and right hippocampus (RH) are prepared. Total RNA are isolated and Northern blot hybridization is performed and quantitated relative to an TNF- $\alpha$  positive control RNA (macrophage = 100%). A marked increase of TNF-  $\alpha$  mRNA expression is observed in LH (104 $\pm$ 17% of positive control,  $p < 0.05$  compared with sham), LC (105 $\pm$ 21%,  $p < 0.05$ ) and LA (69 $\pm$ 8%,  $p < 0.01$ ) in the traumatized hemisphere 1 hr. following injury. An increased TNF-  $\alpha$  mRNA expression is also observed in LH (46 $\pm$ 8%,  $p < 0.05$ ), LC (30 $\pm$ 3%,  $p < 0.01$ ) and LA (32 $\pm$ 3%,  $p < 0.01$ ) at 6 hr which resolves by 24 hr following injury. In the contralateral hemisphere, expression of TNF-  $\alpha$  mRNA is increased in RH (46 $\pm$ 2%,  $p < 0.01$ ), RC (4 $\pm$ 3%) and RA (22 $\pm$ 8%) at 1 hr and in RH (28 $\pm$ 11%), RC (7 $\pm$ 5%) and RA (26 $\pm$ 6%,  $p < 0.05$ ) at 6 hr but not at 24 hr following injury. In sham (surgery without injury) or naive animals, no consistent changes in expression of TNF-  $\alpha$  mRNA are observed in any of the 6 brain areas in either hemisphere at any times. These results indicate that following parasagittal fluid-percussion brain injury, the temporal expression of TNF- $\alpha$  mRNA is altered in specific brain regions, including those of the non-traumatized hemisphere. Since TNF- $\alpha$  is able to induce nerve growth factor (NGF) and stimulate the release of other cytokines from activated astrocytes, this post-traumatic alteration in gene expression of TNF- $\alpha$  plays an important role in both the acute and regenerative response to CNS trauma.

#### **CNS Injury model for IL-1 $\beta$ mRNA**

This assay characterizes the regional expression of interleukin-1 $\beta$  (IL-1 $\beta$ ) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats. Adult Sprague-Dawley rats (n=42) are anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and subjected to lateral fluid-percussion brain injury of moderate severity (2.4 atm.) centered over the left temporoparietal cortex (n=18), or "sham" treatment (anesthesia and surgery without injury). Animals are sacrificed at 1, 6 and 24 hr. post injury, brains removed, and tissue samples of left (injured) parietal cortex (LC), corresponding area in the contralateral

right cortex (RC), cortex adjacent to injured parietal cortex (LA), corresponding adjacent area in the right cortex (RA), left hippocampus (LH) and right hippocampus (RH) are prepared. Total RNA is isolated and Northern blot hybridization was performed and the quantity of brain tissue IL-1 $\beta$  mRNA is presented as percent relative radioactivity of IL-1 $\beta$  positive macrophage RNA which was loaded on the same gel. At 1 hr following brain injury, a marked and significant increase in expression of IL-1 $\beta$  mRNA is observed in LC ( $20.0 \pm 0.7\%$  of positive control,  $n=6$ ,  $p < 0.05$  compared with sham animal), LH ( $24.5 \pm 0.9\%$ ,  $p < 0.05$ ) and LA ( $21.5 \pm 3.1\%$ ,  $p < 0.05$ ) in the injured hemisphere, which remained elevated up to 6 hr. post injury in the LC ( $4.0 \pm 0.4\%$ ,  $n=6$ ,  $p < 0.05$ ) and LH ( $5.0 \pm 1.3\%$ ,  $p < 0.05$ ). In sham or naive animals, no expression of IL-1 $\beta$  mRNA is observed in any of the respective brain areas. These results indicate that following TBI, the temporal expression of IL-1 $\beta$  mRNA is regionally stimulated in specific brain regions. These regional changes in cytokines, such as IL-1 $\beta$  play a role in the post-traumatic.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

## What is Claimed Is:

1. A compound selected from the group consisting of:
  - 5 N-[4-chloro-2-hydroxy-3-(4-methyl-piperazine -1-sulfonyl)-phenyl]-N'-(2-chloro-3-fluorophenyl) urea;
  - N-[4-chloro-2-hydroxy-3-(4-(2-hydroxyethyl)-piperazine-1-sulfonyl)phenyl]-N'-(2-chloro-3-fluorophenyl) urea; and
  - 10 N-[4-chloro-2-hydroxy-3-(1-piperazinylsulfonyl)phenyl]-N'-(2-chloro-3-fluorophenyl) urea or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier or diluent.
- 15 3. A method of treating a chemokine mediated disease, wherein the chemokine binds to an IL-8 a or b receptor in a mammal, which method comprises administering to said mammal an effective amount of a compound according to Claim 1.
4. The method according to Claim 3 wherein the mammal is afflicted with a
  - 20 chemokine mediated disease selected from the group consisting of psoriasis, atopic dermatitis, arthritis (either oseo- or rheumatoid), asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cardiac and renal reperfusion injury, glomerulonephritis,
  - 25 thrombosis, graft vs. host reaction, alzheimers disease, allograft rejections, malaria, restinosis, angiogenesis, atherosclerosis, osteoporosis, gingivitis, viral diseases such as rhinovirus and undesired hematopoietic stem cell release.

(19) World Intellectual Property  
Organization  
International Bureau



27 APR 2005



(43) International Publication Date  
13 May 2004 (13.05.2004)

PCT

(10) International Publication Number  
**WO 2004/039775 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/495**,  
C07D 295/26

(21) International Application Number:  
PCT/US2003/033964

(22) International Filing Date: 28 October 2003 (28.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/421,956 29 October 2002 (29.10.2002) US

(71) Applicant (for all designated States except US):  
**SMITHKLINE BEECHAM CORPORATION**  
[US/US]; PO Box 7929, One Franklin Plaza, Philadelphia,  
PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BUSCH-PE-  
TERSEN, Jakob** [DK/US]; 709 Swedeland Road, King  
of Prussia, PA 19406 (US). **PALOVICH, Michael, R.**  
[US/US]; 709 Swedeland Road, King of Prussia, PA  
19406 (US). **WIDDOWSON, Katherine, L.** [CA/US];  
709 Swedeland Road, King of Prussia, PA 19406 (US).

(74) Agent: **SIMON, Soma, G.**; UW2220, 709 Swedeland  
Road, King of Prussia, PA 10406 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,  
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH,  
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,  
TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO  
patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG,  
ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU,  
TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE,  
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT,  
RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
26 August 2004

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: IL-8 RECEPTOR ANTAGONISTS

(57) Abstract: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).



WO 2004/039775 A3

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/33964

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/495; C07D 295/26.  
US CL : 514/252.12, 544/383.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 514/252.12, 544/383.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
CAS ONLINE STRUCTURE SEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/35442 (SMITHKLINE BEECHAM CORPORATION) 22 June 2000 (22.06.2000), see especially pages 3-4, definition of "Y" and lines 1-2 on p.42.	1-5



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

21 March 2004 (21.03.2004)

Date of mailing of the international search report

22 JUN 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Emily Bernhardt

Telephone No. (571) 272-2717